Allergan Says Weight-Loss Drug Users Saw Skin Look 10 Years Younger

Allergan Aesthetics presented early studies suggesting targeted skincare and DiamondGlow treatments improved skin quality in people on GLP-1 weight-loss drugs.

Allergan Aesthetics, an AbbVie company, announced results from two small, single-center clinical studies evaluating targeted skincare regimens alone and combined with DiamondGlow dermabrasion in individuals taking medical weight loss medications, including GLP-1 receptor agonists. The findings were presented at the 2026 Science of Skin Summit, held September 17–20, 2026, in Austin, Texas, as digital e-posters by authors including Lisa T. Goberdhan and Elizabeth Makino. The skincare regimen included a growth factor serum, a neck cream, and a firming and toning body lotion.

The striking detail both outlets highlight is participant-reported age perception: according to the companies' release as carried by Stock Titan and Investing News Network, participants in the 12-week skincare study said their facial skin appeared approximately 10 years younger after four weeks of twice-daily growth factor serum use. In the six-week study, participants reported facial skin looked about 7.5 years younger after three DiamondGlow treatments plus six weeks of skincare. For readers of GLP-1 'Ozempic face' coverage, a serum claiming a decade of visible age reversal in a month is the kind of claim fans will debate.

The studies were small: the 12-week skincare-only study had nine participants who completed it, while the six-week DiamondGlow-plus-skincare study had 11 participants with at least one post-treatment assessment. Investigators reported statistically significant visible improvements in selected measures — dryness, tone evenness, crepiness, tactile roughness, lines and wrinkles, and texture — as early as week two in the skincare study, and immediately after DiamondGlow treatment in the combination study. Participants reported high satisfaction, though results varied by regimen, treatment area, time point and sample size, and the company itself says larger populations are needed to confirm the findings.

As medical weight loss therapies reshape patient health, interest in associated skin changes — firmness, laxity and crepiness — is growing, Elizabeth Makino, director of clinical development and global scientific affairs for skincare R&D at Allergan Aesthetics, said in the release. The data signal that AbbVie's aesthetics division is positioning products for the exploding GLP-1 population, and Stock Titan noted ABBV gained 0.57% in the September 17 session, a mild positive market reaction. Larger follow-up research will determine whether these early results hold up and inform approaches to patients' evolving aesthetic needs.